Find Out If You Have a Case

Attorney Matthew T. Marin

Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.

Super Lawyers® 2014–2024CALL 24/7(888) 348-2735

Dupixent Lawsuit — Free, Confidential Case Review

Mycosis fungoides after Dupixent? You may qualify.

MF is the most common form of CTCL and is on the qualifying list. Two confidential minutes tells you where you stand.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.

Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?

Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →

No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Attorney Matthew T. MarinOr talk to a person now: (888) 348-2735 — answered 24/7

Attorneys Stefanie A. Murphy and Matthew T. Marin of Marin & Murphy Law Firm

Stefanie A. Murphy & Matthew T. Marin

Partners

Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.

Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.

Mycosis fungoides is the most frequently diagnosed form of cutaneous T-cell lymphoma — a cancer of white blood cells that shows up in the skin. A SEER analysis in JAMA Oncology reported it at about 5.42 cases per million person-years, against 8.55 for CTCL overall. It is known for looking like eczema for years before it is correctly named.

This page is about a lawsuit — it is not medical advice, and filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor.

Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.

What is mycosis fungoides?

Mycosis fungoides is a lymphoma — a cancer of white blood cells called T cells — in which the abnormal cells gather in the skin. The name is a historical accident and has nothing to do with fungus, which is one reason it lands so strangely when a doctor says it out loud. It usually moves slowly, often over many years, and for much of that time it looks like a skin condition rather than a cancer.

How common is mycosis fungoides?

The SEER population-data analysis published in JAMA Oncology in 2022 reported mycosis fungoides at about 5.42 cases per million person-years in the United States, compared with 8.55 per million person-years for cutaneous T-cell lymphoma as a whole. That makes it the largest single share of CTCL diagnoses in that data, and still rare in absolute terms — which is exactly why it is rarely the first thing anyone considers.

What do patch, plaque, and tumor stage mean?

These are the words doctors use for how the disease looks on the skin, and patients pick them up quickly. Patch describes flat discolored areas that may be dry or scaly. Plaque describes thicker, raised areas. Tumor stage describes raised growths. Staging also takes account of whether lymph nodes, the blood, or internal organs are involved. Many people stay in the earlier stages for a long time. What stage applies to you is a question only your treating physicians can answer from your own records and examination.

Why is mycosis fungoides so often called eczema first?

Because early mycosis fungoides and atopic dermatitis can resemble each other both to the eye and under the microscope. A 2026 editorial in the American Journal of Clinical Dermatology describes “considerable clinical and histopathologic overlap between AD and early-stage MF, which may lead to initial misdiagnosis.” People commonly spend years being treated for eczema first, trying cream after cream, before a biopsy points somewhere else. Being misdiagnosed as eczema is the ordinary state of the medicine here. It is not a failure by the patient, and it is not an accusation against the dermatologist who was working with what was known.

How is mycosis fungoides diagnosed?

Through a skin biopsy read by a pathologist, usually with laboratory staining that identifies which surface markers the cells carry — what doctors call immunophenotyping. Testing may also look at whether the T cells present appear to be copies of one cell rather than a normal mixed population. Early biopsies often come back unclear, and it is common for people to have more than one biopsy across months or years before anyone uses the words mycosis fungoides.

How is mycosis fungoides different from Sézary syndrome?

Both are forms of cutaneous T-cell lymphoma. Sézary syndrome is much rarer, involves the blood as well as the skin, and typically presents with widespread redness over most of the body rather than separate patches. Both appear on the list of qualifying lymphoma diagnoses used for Dupixent claims.

Does mycosis fungoides qualify for the Dupixent lawsuit?

Mycosis fungoides is named on the list of qualifying lymphoma diagnoses this firm works from. The list of qualifying subtypes runs to fourteen entries, and the page on who qualifies sets the criteria out in full.

  • A mycosis fungoides diagnosis made after or during Dupixent use.
  • No minimum length of Dupixent use is required.
  • Claims may be brought on behalf of someone who has died, through their estate.
  • If you are not certain which subtype your pathology report names, that does not end the review.

Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases. A review is confidential and carries no obligation.

Free Confidential Evaluation — No Fee Unless There Is a Recovery

(888) 348-2735

Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

What else do people ask about mycosis fungoides?

What is mycosis fungoides?

Mycosis fungoides is a form of cutaneous T-cell lymphoma, a cancer of white blood cells called T cells in which the abnormal cells collect in the skin. Despite the name, it has nothing to do with a fungus. It usually appears as patches or thickened plaques that are itchy and slow to clear.

How common is mycosis fungoides?

A SEER population-data analysis published in JAMA Oncology in 2022 reported mycosis fungoides at about 5.42 cases per million person-years in the United States, against 8.55 per million person-years for cutaneous T-cell lymphoma overall — the largest single share of CTCL diagnoses in that data.

What do patch, plaque, and tumor stage mean?

In everyday terms: patch describes flat discolored areas, plaque describes thicker raised areas, and tumor stage describes raised growths on the skin. Doctors also consider whether lymph nodes, blood, or organs are involved. Only your treating physicians can tell you what stage applies to you.

Why is mycosis fungoides so often diagnosed as eczema first?

Because early mycosis fungoides and atopic dermatitis can look alike both to the eye and under the microscope. A 2026 editorial in the American Journal of Clinical Dermatology describes considerable clinical and histopathologic overlap between the two, which may lead to initial misdiagnosis.

How is mycosis fungoides diagnosed?

Usually through a skin biopsy read by a pathologist, often with laboratory staining that identifies which markers the cells carry, and sometimes testing for whether the T cells look like copies of a single cell. Early biopsies often come back unclear, so repeat biopsies over time are ordinary rather than unusual.

Does a mycosis fungoides diagnosis qualify for the Dupixent lawsuit?

Mycosis fungoides appears by name on the list of qualifying lymphoma diagnoses this firm works from, where the diagnosis was made after or during Dupixent use. Whether any individual has a claim depends on their medical records and the law of their state, which is what a case review looks at.

Does it matter how long I took Dupixent?

The criteria this firm works from set no minimum length of Dupixent use. Some people were on it for years and some for a short time. Your prescription dates, pharmacies, and diagnosis dates are the details a review actually turns on.

What if my biopsy came back inconclusive?

An inconclusive biopsy is common in early mycosis fungoides and does not settle the question either way. If you were eventually given a qualifying diagnosis, the earlier unclear biopsies are part of your record, not a reason to assume you have nothing to review.

Free Confidential Evaluation — No Fee Unless There Is a Recovery

(888) 348-2735

Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Sources
  • “Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis,” JAMA Oncology 2022;8(11):1690–1692 — jamanetwork.com
  • “Dupilumab and Cutaneous T-Cell Lymphoma: A Call for Vigilance, Not Alarm,” American Journal of Clinical Dermatology 2026;27:5–7 — link.springer.com
  • Qualifying-diagnosis list per the referring counsel intake criteria dated February 6, 2026 (on file with Marin & Murphy Law Firm).
  • FDA, “October–December 2024 Potential Signals of Serious Risks Identified from FAERS” — fda.gov
  • National Cancer Institute, Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®), Patient Version — cancer.gov